Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response  by Bosch, Katherine A. et al.
Virology 398 (2010) 115–124
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roTemporal analysis of HIV envelope sequence evolution and antibody escape in a
subtype A-infected individual with a broad neutralizing antibody response
Katherine A. Bosch a,b, Stephanie Rainwater a, Walter Jaoko c, Julie Overbaugh a,⁎
a Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA 98109, USA
b Graduate Program in Pathobiology, University of Washington School of Medicine, Seattle, WA 98195, USA
c Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya⁎ Corresponding author. Division of Human Biolo
Research Center, 1100 Fairview Ave. N, Mailstop C3-168
E-mail address: joverbau@fhcrc.org (J. Overbaugh).
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.11.032a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 October 2009
Returned to author for revision
28 October 2009
Accepted 18 November 2009





Broad neutralizing antibody responseThe origin of broadly neutralizing HIV-speciﬁc antibodies and their relation to HIV evolution are not well
deﬁned. Here we examined virus evolution and neutralizing antibody escape in a subtype A infected
individual with a broad, cross subtype, antibody response. The majority of envelope variants isolated over
the ﬁrst ∼5 years after infection were poorly neutralized by contemporaneous plasma that neutralized
variants from earlier in infection, consistent with a dynamic process of escape. The majority of variants could
be neutralized by later plasma, suggesting these evolving variants may have contributed to the elicitation of
new antibody responses. However, some variants from later in infection were recognized by plasma from
earlier in infection, including one notably neutralization-sensitive variant that was sensitive due to a proline
at position 199 in V2. These studies suggest a complex pattern of virus evolution in this individual with a
broad NAb response, including persistence of neutralization-sensitive viruses.
© 2009 Elsevier Inc. All rights reserved.Introduction
There is a complex interplay between neutralizing antibody (NAb)
responses and viral evolution over the course of HIV-1 infection. The
early stages of infection are characterized by rapid viral escape,
suggesting a role for NAb in driving HIV evolution soon after the
resolution of acute infection (Albert et al., 1990; Richman et al., 2003;
Wei et al., 2003). In turn, as the host responds to these accumulating,
antigenically diverse variants, HIV diversity could contribute to the
generation of a broader repertoire of NAbs. The molecular details of
this so-called “clash of the titans” (Burton et al., 2005) remain
relatively poorly deﬁned, particularly during chronic infection.
Several studies have elucidated aspects of this dynamic in the ﬁrst
1–2 years of infection; these studies suggest that early responses are
rather focused and speciﬁc to the infecting virus (autologous virus),
leading to relatively rapid escape (Gray et al., 2007; Li et al., 2006a,
2006b; Moore et al., 2009; Richman et al., 2003; Rong et al., 2009;Wei
et al., 2003). Less is known about viral changes in response to NAb in
chronic infection. During this period, the NAb responses often
broaden to recognize not only autologous, but also some heterologous
viruses, supporting a role for the evolving viruses in driving new
antibody responses (Albert et al., 1990; Deeks et al., 2006; Richman et
al., 2003).gy, Fred Hutchinson Cancer
, Seattle, WA 98109-1024, USA.
ll rights reserved.Most studies to date have focused either on the early responses
and corresponding sequence variation, or on studies of sequence
populations, rather than individual HIV variants. Thus the molecular
details of envelope escape in relation to autologous antibodies over
the course of a typical HIV infection are not well deﬁned, although
cross-sectional studies of HIV-infected mothers support the notion
that there is often a mixture of neutralization-sensitive and -resistant
variants in most chronically infected individuals (Dickover et al.,
2006; Wu et al., 2006). In one recent study, Mahalanabis et al. (2009)
examined the relationship of autologous neutralizing antibodies and
virus evolution in subtype B-infected individuals with broad antibody
responses who had sustained low-level virus replication without
antiviral treatment. In this study, there was an evolving mixture of
both neutralization-sensitive and neutralization-resistant variants
that was generally associatedwith the level of viral control. Given that
the levels of virus replication are likely to be determined to a large
extent by the properties of the infecting viral strain (Kimata et al.,
1999), these studies provide important insights into the potential of
HIV variants of low replication ﬁtness to elicit robust NAb responses.
To date, there has not been a detailed analysis of HIV evolution in
relation to NAb responses in individuals with a robust viral infection
and a correspondingly broad NAb response. Such a situation may
provide insights into the role that continued virus evolution in
response to NAb escape can play in shaping the breadth of the
antibody response.
Here, we studied envelope evolution over time in an individual
who was identiﬁed as having a notably broadly neutralizing antibody
response in comparison to a group of 70 women at the same stage of
116 K.A. Bosch et al. / Virology 398 (2010) 115–124infection (approximately 5 years post-infection), (Piantadosi et al.,
2009). This subtype A-infected individual had antibodies capable of
neutralizing the majority of a panel of subtype A, B, C, and D variants
(Blish et al., 2007, 2009; Li et al., 2005, 2006b) at levels higher than the
median of the 70 women tested. In this study, we examined temporal
neutralizing antibody responses and evolution of viral envelope
sequences in this individual with broadly neutralizing antibodies. We
also identiﬁed one highly neutralization-sensitive variant and deﬁned
a single amino acid that contributed to this neutralization sensitive
phenotype in a context-dependent manner.
Results
Cloning and characterization of viral envelopes from individual QA255
Plasma from QA255 was identiﬁed as being among the top 5% in
neutralization breadth in a screen of 70 women at a similar stage of
infection that included an initial screen against 6 viruses (Piantadosi
et al., 2009), followed by a more in-depth screen of the 20 women
with the most breadth against a panel of 17 early variants
representing subtypes A, B, C, and D (Blish et al., 2007, 2009; Li et
al., 2005, 2006b). In this analysis, QA255 plasma at 1876 days
(5.1 years) post-infection neutralized the majority of viruses tested at
IC50 values above the median for all women tested (Piantadosi et al.,
2009; unpublished data). This individual had set point viral load of
4.81 log10 RNA copies/ml, which is slightly higher than themedian set
point viral load for this cohort (4.46 log10 RNA copies/ml; Lavreys et
al., 2004).
To determine the timing of development of broad NAb in
QA255, plasmas from various times post-infection from this
individual were screened against a test virus panel that included
four subtype A viruses that had a range of neutralization sensitivities
(Q461d1NQ842d16NQ259d2.26 and Q769b9) (Blish et al., 2007) and
one easily neutralized subtype B virus (SF162; Table 1). Four of ﬁve
viruses tested, including the easy-to-neutralize viruses, SF162 and
Q461d1, were neutralized at all time points tested, starting at
189 days post-infection. The potency of neutralization stayed
roughly constant over time in the case of SF162 (IC50 values
ranging from 473 to 834). By contrast, in the case of subtype A virus
Q461d1, the potency increased from an IC50 of 313 at 189 days
post-infection to a peak IC50 of 1079 at 1174 days post-infection. A
similar increase in potency was observed in the neutralization of a
moderately sensitive variant, Q842d16 (from an initial IC50 of 118 to
consistently greater than IC50 of 500 starting at 462 days post-
infection) and a harder-to-neutralize virus, Q259d2.26 (where the
IC50 values ranged from an initial 62 to a peak of 319). The more
neutralization-resistant virus in this panel, Q769b9, was not
neutralized at detectable levels at 189 days post-infection but was
neutralized at low levels (IC50=38–118) at each of the later times.
The negative control virus, SIVMne CL8 (Overbaugh et al., 1991),
was not neutralized by any of the plasma tested.
Envelope clones were isolated from four times post-infection of
QA255. The earliest and latest time points chosen for cloning, 189 days
post-infection and 1729 days post-infection, respectively, wereTable 1
Neutralizing antibody responses (IC50 values) over time in subject QA255 against a panel o
Virus Days Post-infection
189 days 322 days 462 days 791 days
SF162 473 575 809 673
Q461d1 313 762 810 658
Q842d16 118 198 505 504
Q259d2.26 62 127 264 188
Q769b9 25 47 38 50
SIVMneCl8 25 25 25 25selected to span extensive evolution of envelope and of NAb
responses. Envelope was also cloned from two intermediate time
points, 560 and 662 days post-infection, which were around the
interval where the antibody responses increased in potency. In total,
25 distinct, functional, full-length envelope variants were cloned—6
from 189 days post-infection, 4 from 560 days post-infection, 4 from
662 days post-infection, and 11 from 1729 days post-infection.
A phylogenetic analysis of the 25 functional envelope clones from
individual QA255 showed that this individual was infected with a
subtype A1 virus (Fig. 1), the most common subtype in Kenya
(Neilson et al., 1999; Rainwater et al., 2005). While all variants from
QA255 grouped together in the phylogenetic analysis, the variants
from different time points were intermingled to various extents in the
phylogenetic grouping. Most variants from the earliest time point,
189 days post-infection, were closely related, with three (variants I, J,
and K) almost identical (average genetic distance=0.08%) and three
(C, F, and G) more distinct from each other (average genetic
distance=0.56%) and from the other 189-day variants (average
genetic distance=1.32%). Variants from 560 days post-infection were
more diverse (average genetic distance from each other=1.38%);
however, two of them (variants D and F) showed little divergence
from variants present at 189 days post-infection (average genetic
difference=0.17% from variants 189I, 189J, and 189K). Variants from
662 days post-infection had an average genetic distance from each
other of 0.99%, with none grouping closely with earlier variants.
Envelopes cloned from 1729 days post-infection, as expected, showed
the greatest diversity (average genetic distance from each
other=1.81%), but some were very similar in sequence to much
earlier variants. For example, variant 1729E grouped closely with
variants from 662 days post-infection, and variants 1729A, 1729G, and
1729M grouped closely with variants from 189 days post-infection,
with an average genetic distance from 189-day variants of 0.97%,
compared to an average genetic distance from 189-day variants of
1.89% for all 1729-day variants. Additionally, variants 1729A, 1729G,
and 1729M showed much less divergence from the consensus
sequence of the early variants (1.32% compared to 2.15% for all
1729-day variants).
Characterization of QA255 sensitivity to autologous neutralization
To elucidate patterns of escape from neutralization in individual
QA255, all envelope variants were screened against autologous
plasma, from the contemporaneous time point and from the next
available time point (Fig. 2). A number of viruses were not neutralized
by contemporaneous plasma (represented by gray bars in Fig. 2) but
were by later plasma (represented by white bars in Fig. 2), which is
consistent with what has been seen in prior studies (Wei et al., 2003;
Richman et al., 2003). However, nearly half of the variants, mostly
those present late in infection, were not neutralized by later plasma.
Conversely, 7 of 25 variants (560D, 560F, 662J, 1729A, 1729G, 1729K,
1729M) were potently neutralized not only by later plasma but also
by contemporaneous plasma.
Next, to compare variants from all time points against the same
plasma, all variants were screened against autologous plasma pooledf 6 viruses.
Kenya plasma
pool
1174 days 1512 days 1876 days
834 702 650 1347
1079 807 995 610
510 545 606 182
249 319 257 35
118 88 42 25
25 25 25 25
Fig. 1. Neighbor-joining phylogenetic tree of all functional QA255 envelope clones. A phylogenetic tree was constructed using several reference strains of subtypes (those with
names beginning with A1, A2, B, C, and D) as outgroups. All sequences with the designation QA255 are from the individual examined in this study. The subject ID is followed by the
days post-infection, when the clone was isolated and a letter to designate the PCR. The following symbols also denote the days post-infection: =189 dpi, =560 dpi,■=662 dpi,
Δ=1729 dpi.
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(189, 322, 560, 662, 791, 1729, and 2016 days post-infection) (Fig. 2,
black bars).Most early variantswere sensitive to neutralization by this
pooled plasma, including two (189J and 189K) that were not sensitive
to neutralization by contemporaneous plasma and only weakly so by
plasma from 322 days post-infection, suggesting that an antibody
response effective against these variants was eventually elicited. The
majority of late variants were resistant to neutralization by the pooled
plasma,whichmay be expected given that the pool contained only one
plasma that was later in infection than the envelope variants.
However, several late variants were sensitive to neutralization by
the pooled plasma, with IC50 values ranging from ∼200 to N1600.
These included several of the late variants that clustered with earliervariants on the phylogenetic tree, 1729A, 1729G, and 1729M, all of
which were particularly neutralization-sensitive to individual plasma
samples. The two early variants within this cluster, 189C and 189F,
were also sensitive to neutralization by the pooled plasma, although
less efﬁciently than the later variants 1729A and 1729M.
To more directly address whether antibodies capable of neutral-
izing some of the later variants were present at earlier times, we
examined 4 variants from 1729 days post-infection as well as
representative variants from earlier time points against 6 plasma
samples from 322 days to 1512 days post-infection. As predicted from
the pooled autologous plasma, some of the late stage variants, e.g.,
1729G and 1729M, were neutralized by antibodies present at much
earlier time points (Table 2).
Fig. 2. IC50 values of all QA255 envelope variants against autologous plasma. The IC50 values are plotted in relation to the phylogenetic tree of (Fig. 1). The gray bars show the IC50
value for each functional envelope variant when tested against contemporaneous plasma (189, 560, 662, and 1729 days post-infection); white bars are IC50 values against plasma
from the next available time point (322, 662, 791, and 2016 days, respectively); black bars are IC50 values for each envelope variant against a plasma pool composed of equal parts
plasma from all seven plasmas that were tested individually. Values represent average results from two independent experiments.
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neutralization
To evaluate neutralization sensitivity to heterologous antibodies,
pseudoviruses expressing the panel of cloned QA255 envelopes were
screened against pooled plasma obtained from 30 HIV-positive
Kenyan individuals between 1998 and 2000. For 24 of the 25
envelope variants screened, the pooled plasma either failed to
neutralize virus entry by 50% (N=18) or did so only at the highest
concentration tested, a 1:100 dilution (N=6). However, one variant,
662J, was neutralized by more than 50% at the lowest concentration
tested, a 1:3200 dilution, and was neutralized by 90% at a 1:800
dilution (Fig. 3a). This same variant was also highly sensitive to
autologous antibodies, as described above. To conﬁrm that neutral-
ization of this envelope variant was due to HIV-speciﬁc antibodies,
clone 662J was screened against plasma from an HIV-negative donorTable 2
Autologous neutralizing antibody responses (IC50 values) over time against sequential
envelope variants from QA255.
322 days 462 days 560 days 662 days 791 days 1512 days
189C 124 234 268 803 615 240
189K b100 b100 163 275 255 175
560A b100 b100 b100 b100 b100 b100
662C b100 b100 b100 b100 b100 b100
662J 2133 ND N3200 N3200 N3200 N3200
1729C b100 b100 b100 b100 b100 b100
1729G b100 b100 130 226 225 199
1729M 400 420 1189 1030 1430 1105
1729O b100 b100 b100 b100 b100 80and against autologous preseroconversion serum from individual
QA255; both the heterologous negative plasma and the autologous
negative serum failed to neutralize this variant by 50% at a 1:100
dilution, the highest concentration tested (Fig. 3b). These results
show that most envelope variants from individual QA255, including
those that are sensitive to autologous neutralization, are not sensitive
to neutralization by antibodies from other individuals.
The variant 662J is extremely sensitive to both autologous and
heterologous neutralization, making it very distinct from the other
variants phenotypically, although it is unremarkable phylogenetically
(Fig. 1). Of note, this variant was neutralized effectively (with an IC50
of approximately 1:2000) by plasma from as early as 322 days post-
infection, or approximately 1 year prior to the time of isolation of the
envelope, and at an IC50 of greater than 1:3200 for every later time
point tested (Table 2).
Molecular characterization of the neutralization-sensitive QA255662J
variant
To begin to assess the basis for the extreme neutralization
sensitivity phenotype in clone 662J, its full envelope sequence was
compared to the sequences of all 24 other variants obtained from this
individual. There were three positions at which a unique residue was
present in clone 662J—a glycine to tryptophan mutation in the signal
peptide, a serine-to-proline mutation at position 199 at the base of
the V1–V2 loop on the C-terminal side, and an isoleucine-to-valine
mutation at position 535 in the transmembrane domain of gp41
(Supplemental Figure 1). The latter two mutations were examined
for their effects on neutralization sensitivity. One mutant (662J
P199S) was constructed in which the proline at position 199 was
Fig. 3. Identiﬁcation of an envelope variant that is highly sensitive to heterologous
neutralization. (a) Screen of QA255 envelope variants against plasma pooled from 30
HIV-positive individuals from Kenya. The percent neutralization is plotted against 2-
fold plasma dilutions, and the results for each envelope variant are shown as a line. The
bold line represents the extremely sensitive variant 662J; the other 24 similarly
resistant variants are not individually denoted as their results are similar. The dashed
line represents the 50% neutralization threshold. Values represent average results from
two independent experiments. (b) Speciﬁcity of neutralizing antibodies to 662J.
Triangles represent the same heterologous pooled plasma used in panel a; squares
represent plasma from an HIV-negative donor; diamonds represent autologous serum
from subject QA255 from before HIV seroconversion. The dashed line represents the
50% neutralization threshold. Values are representative of results of two independent
experiments.
Fig. 4. Effect of P199S and V535I mutations on 662J neutralization sensitivity. The
percent neutralization is plotted against 2-fold plasma dilutions of the heterologous
pooled plasma. Squares represent the parental 662J variant, diamonds represent the
corresponding P199S mutant, and triangles represent the corresponding V535I mutant.
The dashed line represents the 50% neutralization threshold. Values are representative
of two independent experiments.
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V535I) was constructed in which the valine at position 535 was
mutated to the consensus isoleucine. 662J V535I had neutralization
sensitivity equivalent to that of the parental 662J, with greater than
90% neutralization up to a 1:1600 plasma dilution. However, 662J
P199S was completely resistant to the heterologous pooled plasma,
similar to the other envelope variants from this individual, with less
than 50% neutralization even at the highest plasma concentration
tested (Fig. 4), implicating the proline at position 199 in deﬁning
neutralization sensitivity.
To determine whether a proline at position 199 could confer a
neutralization sensitive phenotype in other, neutralization-resistant
variants from the same individual, we introduced this change into
8 other variants, sampled from 4 different times post-infection. All of
the envelope variants encoding the S199P mutation had reduced
titers compared to the parental form; four (560A, 662F, 1729C, and
1729O) showed differences of N100-fold; one of these mutants
(1729O) was rendered completely non-infectious by the mutation
(Fig. 5). Conversely, introduction of the reverse P199S mutation into
the neutralization-sensitive variant 662J increased its infectious titer
by approximately six-fold.
The four mutants (189C, 662C, 1729G, and 1729M; Fig. 5) that
yielded pseudoviruses of high-enough titer to be evaluated for
neutralization sensitivity showed a range of effects of the S199P
mutation on neutralization sensitivity. For example, variant 189C and
the mutant 189C S199P were similarly resistant to neutralization by
heterologous plasma, with neither being neutralized by 50% even at
the highest plasma concentration tested. By contrast, variants 662C,1729G, and 1729M were all fully resistant to heterologous neutral-
ization in their parental forms but signiﬁcantly more sensitive in their
S199P mutant forms, with 50% neutralization being reached at
dilutions of 1:353 for 662C S199P, 1:692 for 1729G S199P, and
1:138 for 1729M S199P (Fig. 5). However, no S199P mutant
recapitulated the extreme neutralization sensitivity of variant 662J,
which showed greater than 50% neutralization even by the lowest
concentration of plasma tested. This suggests that other sequence
characteristics of variant 662J may contribute to the phenotype of
extreme neutralization sensitivity.
Contribution of envelope expression levels to neutralization sensitivity of
the 662J variant
Western blot analysis of the parental and S199P mutants showed
that the effect of the mutation on envelope expression generally
paralleled that on infectious titer: envelope expression was consis-
tently reduced in most S199P mutants compared to wild type, with
the exception of 189C. Interestingly, the P199S showed the least
disruption if titer in this virus background. Conversely, the introduc-
tion of the reverse P199S mutation in 662J restored envelope
expression from its very low baseline (Fig. 5).
The effect of the S199P mutation on envelope expression raised
the possibility that the extreme neutralization sensitivity of the 662J
variant encoding this S199P change could be due to its defect in
envelope expression. To address this question, we generated parental
662J pseudoviruses with higher levels of envelope expression and
mutant 662J P199S pseudoviruses with reduced levels of envelope
expression and tested their neutralization sensitivity. To do this, ratios
of envelope-to-backbone were varied in cotransfections, and enve-
lope expressionwasmeasured byWestern blot and normalized to p24
expression. While envelope expression relative to p24 expression did
not increase or decrease in direct proportion to the amount of
envelope transfected, we did generate 662J and 662J P199S prepara-
tions expressing similar levels of envelope (e.g., 662J at 2:1 and 662J
P199S at 1:1). However, even with their envelope incorporation
increased to approximately the level seen in the 662J P199S mutant,
662J preparations remained sensitive to neutralization even at a
plasma dilution of 1:3200, while 662J P199S preparations remained
completely neutralization-resistant even with reduced envelope
expression (Fig. 6). These results indicate that it is unlikely that
impairment of envelope expression alone explains the extreme
neutralization sensitivity of variant 662J.
Fig. 5. Effect of the S199P mutation on envelope expression, infectivity, and neutralization sensitivity in different backgrounds. The top panel shows a comparison of infectious titer
(ﬁrst two bars) and envelope expression levels (last 2 bars) of the wild type and corresponding mutant at position 199. The designation of the wild type envelope variant is shown
below each 4 bar grouping. For 662J, the wild type variant is proline at 199 while the mutant variant is a change to serine, P199S. For all other variants, the wild type variant is serine
at 199 and the mutant variant is a change to proline, S199P. In the table below, titers and envelope expression levels are shown as fold-change from wild type to mutant (P199 to
S199 for 662J, S199 to P199 for all others). The IC50 values are shown below; NDmeans not done because titers were too low; b100means that 50% neutralizationwas not detected at
the lowest dilution tested, 1:100. Values are representative of the results of two independent experiments.
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phenotype
The S199P mutation, besides introducing a proline residue in
place of the highly conserved serine, also disrupts the highly
conserved potential N-linked glycosylation site at N197. To
determine whether the effect of this mutation on neutralization
phenotype was simply due to the loss of the glycosylation site or
whether the proline was itself necessary to confer the phenotype, a
662J P199A mutant envelope was constructed. This variant, like the
parent 662J variant with the proline at position 199, lacks the
conserved potential N-linked glycosylation site at position 197.
However, unlike the parent virus, the P199A mutant was completely
resistant to neutralization (Fig. 7), suggesting that loss of the
predicted glycosylation site alone is not sufﬁcient to confer the
sensitivity phenotype; rather, the speciﬁc presence of the proline
residue at 199 is important.
Discussion
In this study, envelope variants from a single individual with
naturally occurring broad NAb were characterized in detail, with the
goal of deﬁning the process of neutralization escape in both early and
chronic infection in a person with a broad NAb response. While some
envelope variants followed the expected pattern of NAb elicitation
followed by rapid escape, otherswere recognized very poorly or not at
all by autologous NAb. Most surprisingly, some sensitive variants
seemed to persist throughout the course of infection despite the
constant presence of antibodies capable of neutralizing them.
Experiments to characterize the overall neutralization sensitivity of
envelope variants in this individual revealed the presence of one
variant, 662J, that was extremely sensitive to neutralization, and thisphenotype was mapped to a single serine-to-proline mutation at the
base of the V1/V2 loop.
Several studies have provided evidence that NAb typically
rapidly select for escape variants in the ﬁrst years of HIV infection
(Albert et al., 1990; Moore et al., 2009; Richman et al., 2003; Rong
et al., 2009; Wei et al., 2003). Thus, it was surprising to ﬁnd
several variants (including the ultra-sensitive variant, 662J) that
were sensitive to neutralization not only by contemporaneous
antibodies but also by antibodies present several years earlier in
infection. The present study differs from the prior studies in that it
included ∼5 years of follow-up in an individual speciﬁcally
selected for the presence of broadly neutralizing antibodies,
which was not a selection criterion in the prior studies. Our
ﬁnding of persistence of neutralization-sensitive envelope variants
is consistent with results of a recent study (Mahalanabis et al.,
2009) that included individuals selected for both broad neutraliz-
ing antibody and strong control of viremia, studied at time points
late in chronic infection.
Collectively, these studies raise several new questions. First, are
the persistent sensitive variants representative of actively replicating
viruses, and how prevalent are they in the viral population overall?
Because these envelopes were cloned from integrated proviral DNA, it
is theoretically possible that they represent archived rather than
currently replicating virus variants. However, the fact that three of
eleven variants isolated from 1729 days, or nearly 5 years, post-
infection were similar in neutralization sensitivity to variants from
4 years earlier argues against this hypothesis, since HIV-infected
activated T cells have a short half-life (Markowitz et al., 2003;
Perelson et al., 1996, 1997) and latently infected, resting T cells are
rare (Chun et al., 1997). Additionally, other studies have reported
results consistent with these using envelope cloned directly from viral
RNA (Mahalanabis et al., 2009; Skrabal et al., 2005).
Fig. 6. Effect of titrating envelope expression level on 662J and 662J P199S sensitivity to heterologous neutralization. The top panel shows a Western blot, with the ratio of plasmids
encoding the envelope and proviral backbone used for the transfection shown above the blot. To the left, the locations of the proteins of interest are shown. In the lower panel, a
neutralization graph is shown comparing pseudovirus derived from the 662J and 662J P199S (designated 662J PS here) at different envelope-to-backbone ratios, where closed
symbols represent 662J parental variants, with darker shades of gray indicating a greater amount of envelope transfected, and open symbols represent 662J P199S mutant variants,
with darker shades of gray indicating a smaller amount of envelope transfected, as shown in the key at the bottom. The dashed line represents the 50% neutralization threshold.
Plasma used was the heterologous pooled plasma. Values are representative of the results of two independent experiments.
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persist until late in infection in the face of antibodies capable of
neutralizing them and in the presence of contemporaneous virus that
is not sensitive to neutralization by those antibodies? Because
changes in envelope can have major effects on replicative ﬁtness
(Rangel et al., 2003), it is possible that escape carries a cost in
replicative ﬁtness, leading to a balance between more-ﬁt but
neutralization-sensitive variants and less-ﬁt but neutralization-
resistant variants. Another possibility is that neutralization assays
such as the one used here, which measures neutralization of cell-free
virus infection, do not accurately reﬂect the processes of virus
infection and neutralization in an infected individual, which couldFig. 7. Effect of eliminating the position 197 glycosylation site with a P199A mutation.
Plasma used is the heterologous pooled plasma. Closed triangles represent the parental
662J variant and open triangles represent the 662J P199A mutant. The dashed line
represents the 50% neutralization threshold.potentially involve both cell-free and direct cell-to cell virus spread. In
this model, variants identiﬁed as neutralization-sensitive could
persist if they are not neutralized during cell-to-cell spread by
antibodies capable of blocking cell-free virus infection.
QA255 was identiﬁed because she had a broad neutralizing
antibody response at 5 years post-infection relative to other women
in the cohort (Piantadosi et al., 2009). This broad response was
evident as early as 189 days after infection—a time at which 4 of the 5
test viruses examined here were neutralized, as were other variants of
subtypes B, C, and D (data not shown). The development of breadth in
chronically infected individuals may be due to either continued
antigenic stimulation with multiple diverse variants that evolve over
time, as suggested by one recent study (Scheid et al., 2009) or to the
elicitation of antibodies of broad speciﬁcity as recently demonstrated
in one individual with exceptionally broad antibody responses
(Walker et al., 2009), or both. In the individual studied here, there
was a very narrow window of HIV infection prior to the development
of broad neutralizing antibodies, suggesting the possibility that
breadth in this case may be due to the elicitation of an antibody
with broad speciﬁcity. Such individuals are of high interest because
they may hold the clues to identifying antibodies capable of
recognizing highly diverse, circulating HIV variants.
QA255mounted a broad heterologous response despite not having
an unusually potent autologous response. Neutralization potency was
similar or, in some cases, even greater against the heterologous virus
than the autologous early virus. The relatively weak autologous
response in QA255 contrasts with ﬁndings in individuals infectedwith
subtype C viruses, where neutralizing antibodies capable of potently
neutralizing autologous virus, with a median IC50 of 2363, were
observed within the ﬁrst 30 months of infection (Li et al., 2006a). HIV
autologous NAbs tend to target the variable loops of envelope and are
122 K.A. Bosch et al. / Virology 398 (2010) 115–124therefore often type-speciﬁc (Rong et al., 2007; Sagar et al., 2006),
whereas broad NAbs capable of neutralizing circulating strains of HIV
are more likely to target conserved, conformational epitopes such as
the CD4 binding site (Dhillon et al., 2007; Li et al., 2007). Thus, these
data also suggest that the neutralizing antibodies elicited in this
individual recognize a conserved target, leading to broad speciﬁcity.
One env variant in this individual, cloned from 662 days, was
extremely sensitive both to autologous neutralization by plasma from
a wide range of time points and to heterologous neutralization. A
single amino acid change, from a highly conserved serine at position
199 to a proline, was found to be necessary and sufﬁcient to confer
extreme neutralization sensitivity to the variant 662J, though not
sufﬁcient to confer the same phenotype to other envelope variants.
Functionally, this position lies within the bridging sheet that forms
part of the coreceptor binding site (Groenink et al., 1993; Ogert et al.,
2001; Sullivan et al., 1993). Importantly, the S199P mutation also
disrupts a highly conserved predicted N-linked glycosylation site at
N197 that was previously described as contributing to a glycan shield
on the bases of sequence changes that contributed to NAb escape
(Wei et al., 2003). However, here we demonstrated by site-directed
mutagenesis that the phenotypic effect of the mutation is not due to
disruption of the glycosylation site, but rather speciﬁcally requires the
presence of the proline residue. These analyses highlight the potential
limitations of predicting disruption of glycosylation sites based only
on amino acid sequence motifs and underscore the importance of
demonstrating that changes in glycosylation are actually driving the
biological differences, as has been donewith studies of SIV NAb escape
(Chackerian et al., 1997).
While the S199P mutation altered envelope expression levels and
infectivity, changes in the level of envelope expression did not result
in dramatic changes in neutralization sensitivity, indicating that the
neutralization sensitivity of variant 662J is more likely due to changes
in envelope conformation leading to epitope exposure. Amino acid
changes in this region have been shown in other studies to confer CD4
independence (Kolchinsky et al., 2001a; Li et al., 2008), a phenotype
associated not only with extreme neutralization sensitivity (Edwards
et al., 2001; Kolchinsky et al., 2001b) but also with the elicitation of
broad neutralizing antibodies (Li et al., 2008; Zhang et al., 2002, 2007).
It is therefore tempting to speculate that the envelope conformation
responsible for the 662J's neutralization sensitivity may also present
conserved epitopes and thus be related to the development of broadly
neutralizing antibodies in this individual.
These detailed analyses of envelope evolution in a subtype A-
infected individual with typical viral load and a broad NAb response
suggest that neutralizing antibodies do not invariably drive immune
escape in HIV infection. These ﬁndings reveal a complex dynamic
between virus evolution and neutralizing antibody escape that was
not apparent in studies focused on NAb escape at earlier stages of
infection.
Materials and methods
Study subjects and plasma samples
Plasmas and peripheral blood mononuclear cells (PBMCs) were
obtained from an individual in an established prospective cohort of
female sex workers in Mombasa, Kenya (Martin et al., 1994). This
individual, QA255, was enrolled in the study in 1993 when she was
HIV-seronegative, became infected in January of 1998, and provided
regular samples of plasma and PBMCs until being lost to follow-up in
2004. This individual was identiﬁed as having a broad neutralizing
antibody response compared to 70 women in the Mombasa cohort at
the same stage of infection (∼5 years) (Piantadosi et al., 2009;
unpublished data).
A pooled plasma sample was made by combining plasma collected
between 1998 and 2000 from 30 HIV-positive individuals in Kenya,most of whom were also expected to be infected with subtype A
viruses (Blish et al., 2007). All plasmas were heat-inactivated at 56 °C
for 45 minutes before use in neutralization assays.
Isolation of viral envelopes
DNA was extracted from ∼5×106 banked uncultured PBMCs from
QA255 using the QIAamp Blood Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer's instructions. The proviral copy
number in the extracted DNA was measured by real-time PCR
ampliﬁcation of a 300 bp region of pol as previously described
(Rousseau et al., 2004). This copy number was used to dilute DNA to a
single estimated proviral copy per reaction, to avoid recombination
between distinct proviruses during PCR and to avoid selective
ampliﬁcation of particular proviral sequences (Rudensey et al.,
1993). Full-length viral envelope was then ampliﬁed by nested PCR
using the TaqPlus Precision PCR system (Stratagene, La Jolla, CA) as
previously described (Wu et al., 2006). The ﬁrst-round product was
ampliﬁed using the 5′ primer vpr1 (5′-GATAGATGGAACAAGCCCCAG-
3′) and an equimolar mix of the 3′ primers nef24 (5′-TACTTGT-
GATTGCTCCATGT-3′) and nef34 (5′-TACTTGTGACTGCTCCA TGT-3′).
The second-round product was ampliﬁed using 2 μL of the 50 μL ﬁrst-
round reaction product as template, using the 5′ primer vpr11 (5′-
ATACTAAG ACGCGTGAAGCACCCGGGAAGTCAGCCT-3′), which
encodes the MluI restriction site (in bold), and the 3′ primer nef30
(5′-ATATTCTTGCGGCCGCGTCTCGAGATACTGCTCC-3′), which encodes
the NotI restriction site (in bold). The ﬁnal products were then
digested with MluI and NotI, puriﬁed from an agarose gel using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) according to the
manufacturer's instructions, and cloned into the mammalian expres-
sion vector pCI-neo (Invitrogen, Carlsbad, CA), which had been
digested with MluI and NotI and puriﬁed using the QIAquick Gel
Extraction Kit, at an approximate 1:1 vector-to-insertmolar ratio. Each
cloned envelope variant was namedwith a number indicating its time
point in days post-infection followed by a letter identifying the PCR.
Sequence analysis
Envelope variants were sequenced throughout the open reading
frame. Sequence data were analyzed in VectorNTI 10.3.0 (Invitrogen)
and aligned using ClustalX 2.0.8 (Thompson et al., 1997) with
reference sequences from subtypes A1, A2, B, C, and D obtained from
the Los Alamos database (http://www.hiv.lanl.gov/content/hiv-db/
mainpage.html). Sequences were codon-aligned, manually adjusted,
and gap-stripped. A neighbor-joining phylogenetic tree (Saitou and
Nei, 1987) was constructed in ClustalX. Genetic distances were
calculated using the Kimura two-parameter model (Kimura, 1980).
Cells and viruses
To generate pseudovirus with the desired envelope, the cloned
viral envelope of interest was cotransfected into preplated 293T cells
along with a full-length subtype A proviral clone with a partial
deletion in envelope (Q23Δenv) using the Fugene-6 transfection
reagent (Roche, Indianapolis, IN) as previously described (Long et al.,
2002). In most experiments, 1.3 μg of plasmid encoding envelope
(approximately 8 kb) was cotransfected in a T75 tissue culture ﬂask
preplated with 2×106 293T cells with 2.7 μg of plasmid encoding
Q23Δenv (approximately 16 kb), for an approximately equimolar
envelope-to-backbone ratio; in some experiments, the ratio of
envelope-to-proviral backbone was titrated as noted. After 48 hours,
supernatants were harvested and ﬁltered through a 0.22 μm Steriﬂip
Filter Unit (Millipore, Billerica, MA) to remove cellular debris.
Pseudoviruses were initially screened for infectivity on TZM-bl cells,
a HeLa-derived indicator cell line that expresses high levels of CD4,
CCR5, and CXCR4 and also expresses β-galactosidase under the
123K.A. Bosch et al. / Virology 398 (2010) 115–124transcriptional control of the HIV-LTR (Wei et al., 2002). Approxi-
mately one-third of proviral envelopes cloned were not functional as
judged by their inability to infect TZM-bl cells, consistent with results
observed in previous studies (Blish et al., 2009; Long et al., 2002). For
functional pseudoviruses, infectious titer was measured by serially
diluting viruses 10-fold, adding 50,000 TZM-bl cells in suspension in
growth medium containing a ﬁnal concentration of 20 μg/mL DEAE-
dextran, incubating at 37 °C for 48 hours, staining ﬁxed cells for β-
galactosidase activity, and directly counting stained cells.
Neutralization assays
Neutralization assays were performed using pseudoviruses to
infect TZM-bl cells, as described previously (Rainwater et al., 2007;
Wu et al., 2006). Five hundred infectious particles of virus were
incubated with growth medium alone or with serial two-fold
dilutions of heat-inactivated plasma in duplicate or triplicate in a
total volume of 50 μL for 1 hour at 37 °C. A suspension of 10,000 TZM-
bl cells in 100 μL of growthmedium containing a ﬁnal concentration of
20 μg/mL of DEAE-dextran was then added to each well. Neutraliza-
tion assays were incubated at 37 °C for 48 hours and β-galactosidase
activity measured using Galacto-Light Plus reagents (Applied Biosys-
tems, Foster City, CA) on a Fluoroskan FL luminometer (Thermo
Scientiﬁc, Waltham, MA). Percent neutralization was calculated as the
percent reduction in β-galactosidase activity of a virus incubated with
a given dilution of plasma compared to the same virus incubated with
growth medium alone. Percent neutralization was then plotted
against the logarithm of the plasma concentration and a dose-
response curve was ﬁt using Microsoft Excel to calculate the IC50, the
reciprocal dilution of plasma required to inhibit infection by 50%.
Mutagenesis
Site-directed mutagenesis was carried out according to the
manufacturer's instructions for the Quik-Change site-directed muta-
genesis kit (Stratagene). Ten nanograms of plasmid template was
ampliﬁed using Pfu Turbo (Stratagene) and primers containing the
desired base change (sequences available upon request), with
thermocycler parameters of 1 cycle of 30 seconds at 95 °C followed
by 16 cycles of 30 seconds at 95 °C, 1 minute at 60 °C, and 16 minutes
at 68 °C. The PCR product was then digested with DpnI to eliminate
dam-methylated template DNA and electroporated into DH5α
electrocompetent cells. Colonies were screened for the presence of
envelope by digestion with MluI and NotI to produce a 3.2 kb band
corresponding to the full-length envelope. Introduction of the desired
mutation was conﬁrmed by sequencing the region of envelope
containing it; error-free ampliﬁcation of the entire envelope was
veriﬁed for clones containing the desired mutation by sequencing the
entire open reading frame.
Western blot
To measure envelope expression on pseudoviruses, cloned
envelopes were cotransfected with the Q23Δenv backbone in 293T
cells as described above. Aliquots of transfection supernatant were
taken for measurement of infectious titer and neutralization assays;
the remaining transfection supernatant (approximately 7 mL) was
concentrated to 1 mL using an Amicon Ultra 100K Filter Device
(Millipore). This concentrated pseudoviral stock was then pelleted by
microcentrifugation at 16,000×g for 90 minutes at 4 °C, and the pellet
was resuspended in sodium dodecyl sulfate loading buffer with
reducing agent (Invitrogen) and boiled for 5minutes at 95 °C. Samples
were then resolved on a 4–12% gradient Bis–Tris polyacrylamide gel
and transferred to a nitrocellulose membrane. Blots were probed with
rabbit polyclonal sera raised against an SF162 gp140 immunogen
(Doria-Rose et al., 2005) as the primary antibody to measure cleavedand uncleaved envelope, and simultaneously with an anti-p24
monoclonal antibody to measure gag proteins. Secondary antibodies
were a 700DX-conjugated goat anti-rabbit IgG and an 800DX-
conjugated goat anti-mouse IgG (Rockland Immunochemicals, Gil-
bertsville, PA). Imaging and protein quantiﬁcationwere donewith the
Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).Acknowledgments
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